VacLogic+ Maintenance Release 1.5.1 | All Practices: September 24, 2024

Issue Resolutions

Updated forecasting to reflect the recommendation that everyone aged 6 months or older receive a dose of a 2024-25 COVID-19. Forecasting takes into account the age of the child as well as prior historical COVID vaccination in forecasting for Pfizer, Moderna, and Novavax vaccines.

Previously in OP, a child who had completed the primary series or a booster in the 2023-24 COVID season was listed as Series Complete.

VacLogic+ Maintenance Release 1.5.0 | All Practices: September 12, 2024

Forecasting Revisions

Based on FDA / CDC guidelines, this version of VacLogic+ forecasting has been revised to accurately reflect the following recommendations:

High Risk Pneumococcal Series

• Children aged 24-71 months with certain underlying conditions and an incomplete PCV vaccination status should receive either PCV15 or PCV20 according to currently recommended dosing and schedules.
• Children aged 6-18 years with any risk condition who have not received any dose of PCV13, PCV15 or PCV20 should receive a single dose of PCV15 or PCV20. When PCV15 is used, it should be followed by a dose of PPSV23 at least eight weeks later if not previously given.
• Children aged 2-18 years with any risk condition who have received all recommended doses before age 6 years do not need additional doses if they have received at least one dose of PCV20.
• Children with chronic medical conditions who have completed their recommended PCV doses before 6 years of age: If they received PCV13 or PCV15 but not PCV20, they should receive a dose of PCV20 or pneumococcal polysaccharide vaccine (PPSV23) using the previously recommended doses and schedule.
• Children aged 2-18 with immunocompromising conditions who have completed their recommended PCV doses before 6 years of age should receive either a dose of PCV20 OR a dose of PPSV23 (in which case, they should subsequently receive either another PPSV23 or a dose of PCV20 5 years after the first dose of PPSV23)

Issue Resolutions

• Fixed an issue in the vaccine constraint logic to provide a warning when a user attempts to order a DTaP-IPV vaccine (Kinrix) for a patient under 4 or over 7 years old. Previously, the error would pop up if a patient was older than 6 years or if Vaxelis was administered. Now, the popup will only trigger for Kinrix when patients turn 7 years old. The other logic, listed below, remains unchanged:
  
  

  
  

  • Patient is between 4 and 6 years old
  • Patient has had 4 doses of DTaP or DTaP+
  • Patient has had no previous doses of DTaP-IPV
  • Patient has had 3 or more doses of IPV
  • Both DTaP and IPV are due or behind

  
  

  A pop-up alert will display if one or more of the above conditions are not met. Additionally, the chosen patient's status regarding each of the conditions will be displayed in the alert.
• Corrected VL+ forecasting to allow for a change in manufacturers (Pfizer / Moderna) for the 6 month - 4 year old COVID series (2023-24 and beyond). These doses will now forecast as valid. Previously, if a child 6 months - 4 years old received a different manufacturer’s COVID vaccine, it was forecasting as invalid.
• Updated Covid forecasting rules to account for various different historical vaccine schedule logic from multiple schedule changes leading up to the recommendations from the fall 2023 COVID season.
• Corrected the hover text displayed for Covid vaccine to reflect “current formulation of an mRNA vaccine” as opposed to “2023-2024 formulation.”
• Corrected an issue where previously, DEFERRED was displayed in a patient’s Immunization Forecast tab under RSV-Mab (Synagis) even when Synagis was not indicated.